Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna, currently at Vertex Pharmaceuticals, is recognized for his extensive experience in cell therapy. His previous roles include CEO of Semma Therapeutics and Global Program Head at Novartis. The addition of Dr. Sanna is expected to strengthen Adicet’s pipeline, particularly in advancing ADI-001, their allogeneic gamma delta T cell therapy. Adicet focuses on innovative cancer treatments through enhanced immune response and tumor targeting.
Adicet Bio (Nasdaq: ACET), a biotechnology firm, announced its participation in several virtual investor conferences in November and December 2020. These events include:
- H.C. Wainwright Conference on November 12, 2020, at 9:00 AM ET
- B. Riley Securities Panel on November 12, 2020, at 2:00 PM ET
- Stifel Healthcare Conference on November 17, 2020, at 3:20 PM ET
- Evercore ISI HealthCONx Conference on December 1, 2020, at 1:00 PM ET
Live audio webcasts will be available on the company's website, with archived replays for 30 days post-event.
Adicet Bio, Inc. (Nasdaq: ACET) reported its third quarter 2020 financial results on November 5, 2020. Key milestones include the merger completion with resTORbio and FDA clearance for its IND application for ADI-001, a CAR gamma-delta T cell therapy for non-Hodgkin's lymphoma. R&D expenses rose to $8.9 million, while G&A expenses increased significantly to $7.7 million due to merger-related costs, leading to a net loss of $14.8 million. The company ended the quarter with $108.1 million in cash, indicating strong liquidity for future development.
Adicet Bio (Nasdaq: ACET) announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will oversee the development of genetically-modified T cell therapies, enhancing Adicet’s approach to cancer treatment. His extensive experience in cell therapy manufacturing, including roles at KBI Biopharma and Opexa Therapeutics, positions him as a key asset for the company. This leadership addition aims to strengthen the production and clinical development of Adicet's pipeline, especially the ADI-001 therapy, which is designed for improved tumor targeting and immune response.
Adicet Bio (Nasdaq: ACET) has received FDA clearance for its Investigational New Drug (IND) application for ADI-001, an allogeneic gamma delta T cell therapy targeting CD20, aimed at treating patients with B-cell non-Hodgkin's lymphoma (NHL). This significant milestone allows the company to commence its first-in-human clinical trial to assess safety and efficacy in up to 80 patients across various U.S. cancer centers. Interim clinical data is anticipated in 2021, potentially advancing the company's innovative pipeline of CAR gamma delta T cell therapies.
Adicet Bio, a biotechnology firm specializing in gamma delta T cell therapies, announced that CEO Chen Schor and COO Stewart Abbot will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 2:30 PM ET. Investors can access a live audio webcast via Adicet's website, with an archived replay available for 30 days post-event. Adicet is focused on developing innovative cancer therapies utilizing engineered gamma delta T cells for improved tumor targeting and patient outcomes.
Adicet Bio, Inc. (Nasdaq: ACET) announced the cancellation of its proposed public offering of 4,500,000 shares, previously planned due to unfavorable market conditions. The company emphasized its strong financial position, with sufficient capital to meet goals into 2022. CEO Chen Schor highlighted anticipated milestones, including filing INDs for gamma delta CAR-T therapies and initiating Phase 1 studies for non-Hodgkin's lymphoma and other conditions. The company continues to focus on developing innovative allogeneic gamma delta T cell therapies for cancer treatments.
Adicet Bio, a clinical-stage biotechnology company, announced an underwritten public offering of 4,500,000 shares of its common stock, with a potential additional 675,000 shares option for underwriters. The offering, subject to market conditions, aims to raise capital for advancing its gamma delta T cell therapies for cancer treatment. BofA Securities, Jefferies, and SVB Leerink serve as joint book-running managers. The shares will be sold under a shelf registration statement declared effective by the SEC.
Adicet Bio, Inc. (Nasdaq: ACET) announced the grant of 195,898 non-qualified stock options to Nick Harvey, appointed as Chief Financial Officer on September 16, 2020. This option aims to incentivize Mr. Harvey's employment, vesting over four years. The first 25% will vest after one year, with the remaining 75% vesting monthly. Adicet focuses on allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing tumor targeting and immune response through engineered T cells.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Nick Harvey as its new Chief Financial Officer. Harvey brings over 20 years of experience in financial operations and capital markets, having previously served at Centrexion Therapeutics and Radius Health, where he played a key role in its IPO. The company's leadership expressed confidence that Harvey's expertise will support Adicet's strategic growth and advancement of its gamma delta T cell therapy platform.
